What's new? Log in Free sign up

Wave Life Sciences (WVE) News and press releases

Company Profile

News

From Benzinga Pro

Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.

Mizuho Maintains Buy on WAVE Life Sciences, Lowers Price Target to $10

News, Price Target, Analyst Ratings

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $13 to $10.

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $8 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $8 price target.

Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases

Biotech, News, Penny Stocks, Health Care, Small Cap, Movers, General

Wave Life Sciences Ltd (NASDAQ: WVE) announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral sclerosis (ALS) and

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Wave Life Sciences Says WVE-004 Did Not Show Clinical Benefit Compared With Placebo

Wave remains on track to share data from its Phase 1b/2a SELECT-HD study in Huntington's disease investigating WVE-003 in the second half of 2023. The company is also rapidly advancing WVE-N531 for Duchenne muscular

WAVE Life Sciences's Return On Capital Employed Overview

RBC Capital Reiterates Sector Perform on WAVE Life Sciences, Maintains $5 Price Target

News, Price Target, Reiteration, Analyst Ratings

RBC Capital analyst Luca Issi reiterates WAVE Life Sciences (NASDAQ:WVE) with a Sector Perform and maintains $5 price target.

Estee Lauder, NerdWallet, Sprout Social And Other Big Stocks Moving Lower On Wednesday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks mostly traded higher, but the Dow Jones lost around 19 points on Wednesday. Here are some big stocks recording losses in today’s session.

Recap: WAVE Life Sciences Q1 Earnings

WAVE Life Sciences Q1 EPS $(0.27) Misses $(0.04) Estimate, Sales $12.93M Miss $32.33M Estimate

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.04) by 575 percent. This is a 56.45 percent increase over losses of $(0.62) per share from

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-In-Class siRNAs Designed With Wave Platform Chemistry

Biotech, News, General

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats RNAi

Mizuho Reiterates Buy on WAVE Life Sciences, Maintains $13 Price Target

News, Price Target, Reiteration, Analyst Ratings

Mizuho analyst Salim Syed reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $13 price target.

Looking Into WAVE Life Sciences's Return On Capital Employed

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $8 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $8 price target.

Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

Earnings Scheduled For March 22, 2023

Companies Reporting Before The Bell • Boyd Gaming (NYSE:BYD) is estimated to report quarterly earnings at $1.09 per share on revenue of $848.27 million.

WAVE Life Sciences's Earnings: A Preview

Press releases

From Benzinga Pro

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical benefit compared with

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

News, Health Care, Press Releases

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is designed to restore

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Earnings, Press Releases

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human study for WVE-006, the

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

Health Care, Press Releases

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats RNAi is

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Earnings, Health Care, Press Releases

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended leadership in RNA

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.